Tandem Diabetes Care, Inc. (TNDM)

Market Cap	1.41B +26.2%
Revenue (ttm)	1.01B +7.9%
Net Income	-204.71M
EPS	-3.04
Shares Out	68.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	910,021
Open	20.83
Previous Close	20.78
Day's Range	20.10 - 21.62
52-Week Range	9.98 - 29.65
Beta	1.74
Analysts	Buy
Price Target	28.00 (+35.66%)
Earnings Date	May 7, 2026

About TNDM

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It’s flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body. In addition, it offers Tandem Device Updater used to update the pump software from a pe...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Nov 14, 2013
• Employees: 2,500
• Stock Exchange: NASDAQ
• Ticker Symbol: TNDM
• Website: https://www.tandemdiabetes.com

Financial Performance

In 2025, Tandem Diabetes Care's revenue was $1.01 billion, an increase of 7.93% compared to the previous year's $940.20 million. Losses were -$204.71 million, 113.2% more than in 2024.

Analyst Summary

According to 19 analysts, the average rating for TNDM stock is "Buy." The 12-month stock price target is $28.0, which is an increase of 35.66% from the latest price.

Price Target

$28.0

(35.66% upside)

Analyst Consensus: Buy